『Making it in Manufacturing』のカバーアート

Making it in Manufacturing

Making it in Manufacturing

著者: ARTO Talent
無料で聴く

今ならプレミアムプランが3カ月 月額99円

2026年5月12日まで。4か月目以降は月額1,500円で自動更新します。

概要

97% of our listeners don't realise they aren't followed, please double check, thank you!


Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series, spotlighting the leaders shaping the future of manufacturing, engineering and CDMOs in Life Sciences.


Each episode dives into the careers, decisions, and defining moments of industry mainstays - revealing the stories and insights behind real-world impact within the life science manufacturing and CDMO space.


If you're a leader in the space - or aspiring to be - this podcast is a must watch. The series is available on YouTube, Spotify, Apple Podcasts and all major platforms.

Hosted on Acast. See acast.com/privacy for more information.

ARTO Talent
出世 就職活動 生物科学 科学 経済学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Inside the Race to Scale ADCs - Ian Glassford
    2026/05/07

    What does it take to scale complex biologics manufacturing while keeping speed, quality, and communication aligned? In this episode, Ian Glassford explains how integrated CDMO partnerships are helping biotech companies accelerate ADC and bioconjugate programs from discovery through to commercial manufacturing.


    This week on Making It In Manufacturing, Harry Sloan sat down with Ian Glassford, VP at Abzena, with more than a decade of experience spanning medicinal chemistry, synthetic chemistry, bioconjugation, biologics manufacturing, and CDMO leadership roles across GSK and Abzena.


    In this episode, Ian Glassford covers:


    • How Abzena approaches integrated ADC and bioconjugate manufacturing across discovery, development, and GMP production (00:00)


    • Why communication and true partnership models are becoming critical for CDMOs supporting fast-moving biotech programs (02:55)


    • The balance between speed to clinic, process standardisation, and maintaining manufacturing quality in complex biologics (03:37)


    • Ian’s transition from medicinal chemistry at @GSK into leadership within the bioconjugation and ADC space at Abzena (08:11)


    • Where the future of ADCs, AOCs, radionuclide conjugates, and commercial manufacturing is heading over the next five years (10:25)


    For anyone working across biologics manufacturing, ADC development, CDMO partnerships, or complex therapeutics, this conversation offers a practical look at how experienced operators are adapting to increasingly demanding timelines and evolving modalities across the biotech industry.


    Follow ARTO:

    LinkedIn: https://www.linkedin.com/company/artotalent

    Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

    Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

    TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

    Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

    Website: https://arto-talent.com/

    Youtube: https://www.youtube.com/@artotalent


    Ian Glassford:

    LinkedIn: https://www.linkedin.com/in/ian-glassford-phd-mba-28270529/


    Harry Sloan:

    LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/?skipRedirect=true


    Timestamps:

    00:00 Introduction and live recording from DCAT Week in New York

    00:39 Ian Glassford explains Abzena’s role in the ADC and bioconjugate CDMO market

    01:25 The biggest operational challenges in ADC and AOC manufacturing

    02:43 What biotech clients are really looking for beyond technical expertise

    03:37 Managing the balance between speed, quality, and execution

    04:53 How integrated CDMO and CRO models improve timelines and supply chain control

    06:43 The importance of communication and partnership in complex programs

    08:11 Ian’s career journey from medicinal chemistry into bio conjugates

    10:00 Transitioning from hands-on science into site leadership

    10:25 Where Abzena and the wider ADC market are heading in the next five years

    11:51 Adapting CDMO models to support evolving biologics modalities

    12:29 Closing thoughts


    #MakingItInManufacturing #ARTOTalent #Biotech #CDMO #Biologics #ADC #DrugDevelopment #Manufacturing #Pharmaceuticals #Bioconjugates

    Hosted on Acast. See acast.com/privacy for more information.

    続きを読む 一部表示
    13 分
  • How Samsung Biologics Is Redefining CDMO Partnerships - John Gagliardi
    2026/05/05

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.


    How do leading CDMOs move beyond scale to become true strategic partners?


    This week on Making It In Manufacturing, Harry Sloan sat down with John Gagliardi, Sales Director, Key Account Management at Samsung Biologics, with 25+ years of experience spanning operations, supply chain, procurement, sourcing and commercial leadership across biopharma, including previous experience at GSK and leadership in CDMO partnerships.


    In this episode, John Gagliardi covers:


    - How Samsung Biologics has evolved as a pure-play CDMO, including US expansion and the value of integrated support from clinical development through commercial supply.

    - Why long-term partnerships in biomanufacturing depend on value creation beyond capacity, from lifecycle management to flexible supply chain strategies.

    - What credible ADC capability really looks like, including integrated manufacturing, simplified supply chains and how co-located operations can accelerate speed to market.

    - The strategic importance of the Lilly Gateway Labs collaboration with Eli Lilly, and how incubating early-stage biotech can strengthen the future innovation ecosystem.

    - Where growth is heading next for Samsung Biologics, from Bio Campus expansion and emerging modalities to scaling quality while maintaining operational agility.


    If you are interested in where biomanufacturing partnerships are heading, and how leading CDMOs are thinking beyond capacity alone, this conversation offers practical insight worth your time.


    Watch the full episode to hear how John approaches growth, innovation and patient impact through a commercial and operational lens.


    Follow ARTO

    LinkedIn: https://www.linkedin.com/company/artotalent

    Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

    Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

    TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

    Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

    Website: https://arto-talent.com/

    Youtube: https://www.youtube.com/@artotalent


    John Gagliardi

    Sales Director at Samsung Biologics

    LinkedIn: https://www.linkedin.com/in/john-gagliardi-7a8a252/


    Harry Sloan

    CDMO BD Lead at ARTO

    LinkedIn: linkedin.com/in/harry-sloan-605620154/?lipi=urn%3Ali%3Apage%3Ad_flagship3_profile_view_base%3B7ieBaX%2FATH6lSPMIPdsI8w%3D%3D


    Timestamps:

    00:00 Introduction from New York and conference spotlight

    00:42 Samsung Biologics as a pure-play CDMO

    02:10 Building strategic customer partnerships

    03:45 Differentiation beyond standard CDMO models

    05:01 Building credibility in ADC manufacturing

    07:53 Technical collaboration and winning partnerships

    09:07 Lilly Gateway Labs collaboration

    11:40 Growth trajectory and future modalities

    13:19 Scaling while maintaining quality

    15:00 Patient impact and personal motivation

    16:35 Closing remarks


    #MakingItInManufacturing #ARTOTalent #Biomanufacturing #CDMO #Biopharma #SupplyChain #ADC #PharmaceuticalManufacturing #BiotechLeadership

    Hosted on Acast. See acast.com/privacy for more information.

    続きを読む 一部表示
    17 分
  • We Just Built a $1.5B Biologics Company… And We're Here to Disrupt the Industry - Joon Chang
    2026/04/28

    What does it really take to build credibility as a new CDMO in a highly competitive biologics market, while staying grounded in patient impact?


    This week on Making It In Manufacturing, Harry Sloan sat down with Joon Chang, Chief Business Officer at Lotte Biologics, with years of experience spanning Pharma, CDMO, project management, and business development roles across global organisations.


    In this episode, Joon Chang covers:

    • (02:17) Building credibility as a new CDMO and overcoming the challenge of limited track record while leveraging experienced talent from legacy manufacturing sites

    • (03:05) Why people and expertise matter more than company age when delivering successful tech transfer, development, and manufacturing outcomes

    • (04:17) The importance of tailoring partnerships to individual client needs and building long-term relationships across Pharma and biotech organisations

    • (07:00) Career journey from bench scientist to commercial leadership, and how experience across Pharma and CDMO environments shapes client-centric thinking

    • (10:10) Creating a patient-centric culture in manufacturing and commercial teams, and why connecting daily operations to patient impact strengthens partnerships


    If you are interested in how emerging CDMOs can differentiate themselves through culture, capability, and client alignment, this episode offers a grounded and practical perspective worth your time.


    Follow ARTO

    LinkedIn: https://www.linkedin.com/company/artotalent

    Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

    Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

    TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

    Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

    Website: https://arto-talent.com/

    Youtube: https://www.youtube.com/@life_sciences


    Joon Chang

    LinkedIn: https://www.linkedin.com/in/joon-chang-a337895/


    Harry Sloan

    LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

    Timestamps:


    00:00 Introduction at the DCAT Conference

    00:33 Overview of Lotte Biologics and market positioning

    01:20 Capabilities in biologics manufacturing and conjugation

    02:01 Challenges of entering the CDMO market as a new player

    03:05 Importance of talent and retained expertise from legacy sites

    03:52 Building relationships with Pharma and biotech clients

    04:24 Dual hub model across the US and South Korea

    05:01 Manufacturing scale advantages and commercial readiness

    06:19 Speed, cost efficiency, and internal tech transfer benefits

    07:00 Career journey from Pharma to CDMO leadership

    08:04 Understanding client mindset from both Pharma and CDMO perspectives

    08:54 Project management experience and client relationship ownership

    09:43 Leadership philosophy and full lifecycle thinking

    10:10 Building an ideal organisational culture

    10:40 Patient-centric approach and ultra-rare disease considerations

    11:43 Connecting operations to patient impact

    12:34 Applying culture to commercial and sales teams

    13:21 Business development mission and value creation

    13:40 Leadership approach and empowering teams

    15:00 Vision for disrupting the CDMO industry

    16:21 Growth, partnerships, and expanding patient reach

    17:01 Personal motivation and purpose behind the work

    18:00 Team culture and collaboration


    #MakingItInManufacturing #ARTOTalent #Biologics #CDMO #Pharma #Biotech #Manufacturing

    Hosted on Acast. See acast.com/privacy for more information.

    続きを読む 一部表示
    18 分
adbl_web_anon_alc_button_suppression_c
まだレビューはありません